Hemostasis of patients with non-Hodgkin lymphoma and anticardiolipinic antibodies

Abstract

Background Anticardiolipin antibodies are autoantibodies that erroneously recognize cardiolipins on the outside of cell membranes, causing hemostasis disorders, which affect the therapeutic conduct, effectiveness of treatment and quality of life of patients with malignant lymphoma. Purpose Identification of hemostasis changes in primary patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL) Material and methods The study included 83 newly patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; aCL antibodies, antiβ2glycoprotein I IgG, IgM by ELISA method. Hemostasis disorders were evaluated according to the morphological type of NHL, stage, tumor size. Results aCL were detected in 10 (12%) patients with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies and 10% IgG antiβ2glycoprotein I. Hemostasis disorders were found in 6 (60%) patients: thrombosis-at 4 (40%) with mantle cell lymphoma, small lymphocytic lymphoma, lymphoblastic NHL in 75% local stage (I and II), but with a large tumor component (> 11 cm), and hemorrhage at 2 (20%) with stage IV small lymphocyte lymphoma, in which immune thrombocytopenia developed. Conclusions The presence of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis changes in NHL patients, especially thromboembolic events.